We used 5 0 rapid amplification of cDNA ends PCR (Invitrogen, Paisley, UK) to characterize the fusion, employing reverse primers derived from sequences located downstream of known PDGFRB breakpoint locations. The resulting PCR products were cloned and sequencing revealed an in-frame mRNA fusion between full-length ETV6 exon 7, 34 bp derived from ETV6 intron 7 and a truncated PDGFRB exon 12 (Figures 1b and 2 ). The presence of the fusion was confirmed by RT-PCR and by amplifying and sequencing fusion point from genomic DNA (not shown).
The PDGFRB sequence retained in the novel fusion is downstream of the PCR primer we had initially used, explaining why ETV6-PDGFRB was not detected. To determine if we might have missed other similar cases, we analyzed 10 cases with a t(5;12) who tested negative for ETV6-PDGFRB using primers ETV6.Ex2F (5 0 -TCAGGATGGAGGAAGACTCG-3 0 ) and PDGFRB.Ex14R (5 0 -CCCCAACAGGTTGACCACGTTCAG-3 0 ). All were negative, indicating that this variant is not common, but nevertheless we now routinely use these primers to screen t(5;12) cases.
This unusual fusion in our case is reminiscent of that seen for FIP1L1-PDGFRA, for which breaks almost always fall within PDGFRA exon 12 and FIP1L1 intron-derived sequence is frequently incorporated into the mature mRNA. 6 As a consequence, the PDGFRa autoinhibitory WW-like domain is disrupted resulting in partner protein-independent activation of the kinase moiety. 7 The disruption of PDGFRb WW-like domain in our case is unexpected in view of the fact that ETV6 encodes a dimerization domain that is required for transformation by 'normal' ETV6-PDGFRB.
It is notable that our case presented with advanced phase disease. The fusion retained ETV6 exons 1-7, in common with that described by Tokita et al. 3 in a case that also presented with advanced features. In contrast to the most common fusion involving ETV6 exons 1-4, these variants are predicted to encode a chimaeric protein that retains the ETV6 internal and ETS DNA-binding domains. It is possible that retention of these domains leads to a more aggressive phenotype; however, it would be premature to draw any clear conclusions from just two cases. It is noteworthy, however, that our case responded well to imatinib despite being treated in advanced phase. Good responses to imatinib have been described for FIP1L1-PDGFRA-associated CEL in transformation 8 and this may be a general feature of diseases associated with PDGFR fusions.
In summary, it appears that breakpoint diversity for the ETV6-PDGFRB fusion is more common than originally reported.
Screens for this fusion should employ primers capable of detecting all variants in order to provide an accurate molecular diagnosis and appropriate clinical management. We read with interest the article by Karlsson et al. 1 in Leukemia (2007), which reports five patients treated successfully with alemtuzumab (anti-CD52) for refractory autoimmune hemolytic anemia (AIHA) complicating B-cell chronic lymphocytic leukemia (B-CLL). AIHA occurs in about 5% of patients with B-CLL and requires treatment including corticosteroids, cytotoxic drugs, splenectomy or immunosuppressive drugs. 2 Recently, rituximab (anti-CD20) has been used with efficacy in AHAI complicating B-CLL. 3 But relapses are frequent and some patients become refractory.
We report the case of a 69-year-old woman who presented B-CLL complicated by AIHA. B-CLL was diagnosed in 1994 and was treated with different chemotherapy regimens (chlorambucile, cyclophosphamide and then fludarabine) between 1994 and 2002. In October 2003 chlorambucile was introduced for progressing B-CLL; the direct antiglobulin test (DAT) was negative. In March 2004 the patient was hospitalized in our institution for AIHA; hemoglobin (Hb) concentration was 6.4 g/dl with positive DAT. She required transfusions and corticosteroids were started at the dose of 1.5 mg/kg/day. Because of the no-response on Hb concentration and the progressive B-CLL, we decided to use alemtuzumab instead of rituximab. Alemtuzumab was intravenously administrated at conventional doses (30 mg three times weekly) for 8 weeks and corticosteroids progressively decreased from 1 to 0.5 mg/kg/day. After 1 month, Hb concentration rose to 12 g/dl in the absence of further transfusion and DAT became negative; corticosteroids were progressively reduced and stopped in February 2005. In July 2006, CLL progressed and cyclosphamide was reintroduced. Two months later AIHA relapsed with positive DAT, Hb concentration of 8.0 g/dl requiring red blood cell transfusion and corticotherapy at 1 mg/kg/day. Because of the initial efficiency of anti-CD52, we decided to reintroduce subcutaneous alemtuzumab for 11 weeks. Steroids were progressively decreased. Three months after the end of treatment with alemtuzumab, the DAT was negative, and the Hb level and the blood cells count normal. No adverse effect could be observed during this period. Reply to Rituximab activity in CD20 positive multiple myeloma We read with great interest the paper by Moreau et al. 1 on rituximab (anti-CD20 chimeric monoclonal antibody) activity in CD20 þ multiple myeloma (MM). In particular, they treated 14 MM patients expressing CD20 on at least 33% of tumor cells either in untreated stage I or in stage III at relapse after two lines of chemotherapy. Only a single patient pretreated and expressing CD20 in 100% of cells experienced a minor response, and the rest did not respond. We would like to share our experience and make few comments since we recently treated one MM patient who achieved a complete response that was immunofixation negative following treatment with rituximab.
A 54-year-old male was diagnosed with MM IgG/k in April 2005 because of skeletal evidence of multiple osteolytic lesions after a preexistent 1 year diagnosis of monoclonal gammapathy of undetermined significance. At the time of progression to MM, bone marrow biopsy showed 50% monoclonal CD38 þ , CD138 þ plasma cells infiltration; 100% were expressing CD20. Monoclonal component (MC) was 4.0 g/l, while serum calcium and creatinine were normal and b2-microglobulin was 2.3 mg/l. The patient was treated with thalidomide at the dose of 200 mg/day and pulsed dexamethasone administered at the dose of 40 mg/day on days 1-4, 9-12 and 17-20 (odd cycles) and 40 mg/day for 4 days on even cycles, repeated monthly for 4 months. Patient proceeded to PBSC collection in August 2005 after high-dose cyclophosphamide (7 g/m 2 ) and granulocytecolony stimulating factor (5 mg/kg/day). In the previous trials, patients with CD20 þ MM did not show a response to rituximab, but they were not selected according to CD20 expression. 2, 3 In fact, as correctly reported by the authors, several factors have been described to explain resistance against rituximab in a variety of B-cell malignancies such as the level of CD20 expression, dissociated action of complement-dependent cytotoxicity and antibodydependant cellular cytotoxicity. These mechanisms could explain the marginal activity of rituximab as single agent in CD20 þ MM, and introduce the idea that timing of administration (especially after high-dose therapy regimens) also could be useful in reducing minimal residual disease. In fact, we are totally aware that this result, although impressive, has been achieved in only a single patient. But, on the other hand, we believe that in a particular subset of patients with MM expressing CD20, rituximab could have a clinical impact. Moreover, it was always used alone in patients with high tumor burden and never in combination with other agents (i.e. lymphoproliferative-like regimens). We believe that rituximab may exert a more effective activity when administered in patients with low tumor burden and/or sequentially in combination with other agents.
In conclusion, effect of rituximab on CD20 þ MM should be evaluated in prospective, larger, well-designed trials, before dropping a possible tailored therapy in myeloma.
JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases Owing to the high incidence of the V617F point mutation in the JAK2 gene on 9p24 in the BCR-ABL-negative chronic myeloproliferative diseases (CMPD), molecular screening for the respective mutation achieved a key role for patients with polycythemia vera (PV), essential thrombocytosis (ET), chronic idiopathic myelofibrosis (CIMF) and in cases with the suspicion of a CMPD. [1] [2] [3] The mutation was further detected in some cases of chronic myelomonocytic leukemia (CMML), 1, 3, 4 and was reported in acute myeloid leukemia (AML) in lower frequencies, but the number of analyzed cases so far is limited. 1, 3, [5] [6] [7] In addition, the association of JAK2V617F to certain cytogenetic aberrations remains to be clarified.
To further improve understanding of the cooperating role of JAK2V617F with other genetic markers, we screened 1372 patients with various CMPD and AML by a melting curve-based assay and correlated the results to cytogenetic data. The cohort was composed of 681 males and 691 females with a median age of 63.2 years (range ¼ 16.4-90.1). Within the total cohort, 1103 patients had a diagnosis of CMPD (PV: n ¼ 179 patients; CIMF: n ¼ 60; ET: n ¼ 205) and 632 cases had chronic myeloproliferative disorders, which could not be clearly classified (CMPD-U). In addition, 27 patients with the myeloproliferative form of CMML and 269 patients with AML were included (de novo AML: n ¼ 178; secondary acute myeloid leukemia (s-AML) after CMPD: n ¼ 27; s-AML after myelodysplastic syndrome (MDS): n ¼ 25; therapy-related AML (t-AML) after treatment of a previous malignancy: n ¼ 39) (median age ¼ 63. JAK2V617F mutational screening was performed either on bone marrow or on peripheral blood samples (in the CMPD, 30% on bone marrow and 70% on peripheral blood; in AML, 95% on bone marrow and 5% on peripheral blood). A melting curve-based LightCycler assay was performed with the forward primer as described previously. 8 The sensitivity of this assay as estimated by limited dilution assays of JAK2V617F mutated in JAK2V617F unmutated cDNA was 1:100. Homozygosity was defined as JAK2mut/wild type ratios of 41. This remains an approximation and might be an underestimation; however, cases with apparent heterozygosity may be misinterpreted due to a mixture of homozygous and healthy cells in samples with lower percentages of JAK2V617F mutated cells.
In the patients with a CMPD, we found the JAK2V617F mutation in 662/1103 of all cases (60.0%). The mutation rate was highest in PV (153/179; 85.5%), being followed by ET (123/205; 60.0%), CIMF (36/60; 60.0%) and CMPD-U (345/632; 54.6%; Table 1 ). These frequencies were in the range of previous studies. [1] [2] [3] CMML showed a lower frequency of JAK2V617F with 5/27 cases (18.5%). In AML, the overall JAK2 mutation rate of all analyzed AML cases was not calculated because this group was selected showing an overrepresention of s-AML after CMPD. In de novo AML, 11/178 selected AML cases were JAK2V617F mutated, whereas in s-AML following a CMPD, the mutation rate was higher with 16/27 cases (59.3%) equally to the rate of JAK2 mutations in the CMPD. In the cohort with s-AML after MDS, there was no mutated case. In t-AML, the JAK2 mutation rate was 2/39 (5.1%). With two exceptions in the CMPD 8 cohort, all mutations showed the previously described 1849g4t exchange leading to a valine to phenylalanine substitution at codon 617.
Homozygous mutations were most frequent in PV (106/153; 69.3%), closely followed by CIMF (20/36; 55.6%) and CMPD-U (166/632; 48.1%). In ET, the homozgyous mutation rate was lowest (19/123; 15.4%). In CMML, one of two mutated cases was homozygous. In de novo AML 7/11 cases were homozygously mutated, in s-AML following a CMPD 9/16 cases (56%), and in t-AML both JAK2 mutated cases were heterozygous.
In the cohorts with CMPD, aberrant karyotypes were most frequent in CIMF (12/23; 52.2%), being followed by PV (19/83; 22.9%). In CMPD-U, the karyotype aberration rate was 43/347
